BEIJING: China’s medical products regulator said on Saturday it has given conditional approval for Pfizer’s Covid-19 medicine Paxlovid to treat adults with mild to moderate disease who have high risk of progressing to a severe condition.
The National Medical Products Administration said further study on the drug needed to be conducted and submitted to the authority.
The National Medical Products Administration said further study on the drug needed to be conducted and submitted to the authority.